

SUPPLEMENTARY MATERIALS

Title: Co-enrichment of cancer-associated bacterial taxa is correlated with immune cell infiltrates in esophageal tumor tissue

Authors: Greathouse, KL*^{1,2}, Stone, JK*³, Vargas, AJ⁴, Choudhury, A¹, Padgett, N⁵, White, JR⁶, Jung, A¹, Harris, CC³

Author Affiliations:

1. Department of Biology, Baylor University, Waco, TX
2. Nutrition Division, Human Sciences and Design, Baylor University, Waco, TX
3. Center for Cancer Research, National Cancer Institute, Bethesda, MD
4. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
5. Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA
6. Resphera Biosciences, LLC, Baltimore, MD

*Co-first authors

^Corresponding author




Fig. S1: Alpha and beta diversity are variable across cohorts.

Alpha diversity within the NCI-MD and TCGA cohorts. **A-C** Violin or box plots indicate median values with upper and lower quartiles. Significance determined by Kruskal-Wallis test. **C** Alpha diversity in **B** TCGA RNA-seq and **C** WGS cohorts. Boxplots indicate median values with upper and lower quartiles. Significance determined by Wilcoxon test. **D-E** Beta diversity within the NCI-MD case control study determined by Bray-Curtis. **E** Compositional PCoA biplot of beta diversity with arrows signifying highly ranked taxonomic features contributing the most difference. Significance determined by PERMANOVA test. For all graphs, n.s. not significant, * $p < 0.05$.




Fig. S2: Taxa abundance are not associated with risk factors for esophageal cancer in NCIMD cohort. Taxa abundance in NCI-MD case control study for **A** tissue type, **B** gender, **C** histology, **D** race, **E** smoking status, and **F** stage. For all graphs, violin plots indicate median values with upper and lower quartiles. Significance was determined by Kruskal-Wallis test n.s. not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Fig. S3 - Taxa abundance are not associated with *TP53* mutation status in ESCA TCGA WGS and RNA-seq cohort. Taxa abundance TCGA WGS study for *TP53* mutation status in **A** WGS and **B** RNA-seq dataset. For all graphs, violin plots indicate median values with upper and lower quartiles. Significance was determined by Kruskal-Wallis test n.s. not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Fig. S4: Heatmap of taxa co-enrichment networks as determined by SparCC.

A Taxa enrichment heatmap for NCI-MD case control study with underlying data for network depicted in Fig. 3A. **B** Taxa enrichment heatmap for TCGA RNA-seq with underlying data for network depicted in Fig. 3B. **C** Taxa enrichment heatmap for TCGA WGS with underlying data for network depicted in Fig. 3C. Data was calculated for each heatmap as described in Fig. 3.




Fig. S5: Heatmap of immune cells significantly enriched or depleted in tumors with high carriage of ESCA-enriched taxa.

A RNA-sequencing was performed on NCI-MD patients ($n = 27$; non-tumor = 13, BO = 4, tumor = 10) and samples were analyzed for predicted cell infiltration using xCell (citation). Cell infiltrates and taxa abundance were correlated using Spearman's coefficient. **B** Correlation of xCell predicted cell infiltration in TCGA RNA-seq patients with taxa abundance. All correlations shown were sig. $p < 0.05$.




Fig. S6: MEP infiltration is lower in taxa-positive tumors.

Quantification of predicted megakaryocyte-erythroid progenitor (MEP) cell infiltration in the tumor tissues of NCI-MD case control study (top) and TCGA RNA-seq (bottom) present or absent for the indicated taxa. Tumors classified as “present” had one or more reads for the given taxa. MEP infiltration predicted by xCell as described in Fig. 4. Significance determined by Wilcoxon test, n.s. not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Fig. S7: Platelet infiltration trends higher in taxa-positive tumors.

Quantification of predicted platelet infiltration in the tumor tissues of NCI-MD case control study (top) and TCGA RNA-seq (bottom) present or absent for the indicated taxa. Tumors classified as “present” had one or more reads for the given taxa. Platelet infiltration predicted by xCell as described in Fig. 4. Significance determined by Wilcoxon test, n.s. not significant, * $p < 0.05$.

Primary Cohort (NCI-MD Samples)

Description	Esophageal adeno- carcinoma tissues	Esophageal squamous cell carcinoma tissue	Esophageal adeno- carcinoma- adjacent tissues	Esophageal squamous cell carcinoma- adjacent tissue	Barrett's Esophagus tissue	Total
N samples	74	17	87	27	8	213
Sex (N, %)						
Male	65 (87.8)	9 (52.9)	77 (88.5)	14 (51.9)	8 (100)	173 (81.2)
Female	9 (12.2)	8 (47.1)	10 (11.5)	13 (48.1)	0 (0.0)	40 (18.8)
Race (N, %)						
European American	72 (97.3)	10 (58.8)	85 (97.7)	16 (59.3)	8 (100)	191 (89.7)
African American	1 (1.4)	6 (35.3)	1 (1.1)	9 (33.3)	0 (0.0)	17 (8.0)
Other	1 (1.4)	1 (5.9)	1 (1.1)	2 (7.4)	0 (0.0)	5 (2.3)
Age, mean $\pm$ SD	60.3 +/- 10.6	60.7 +/- 9.3	61.9 +/- 11.0	58.7 +/- 9.2	65.9 +/- 6.0	61.0 +/- 10.4
BMI (N, %)						
underweight	1 (1.4)	2 (11.8)	1 (1.1)	5 (18.5)	0 (0.0)	9 (4.2)
normal weight	21 (28.4)	9 (52.9)	19 (21.8)	11 (40.7)	1 (12.5)	61 (28.6)
overweight	24 (32.4)	5 (29.4)	27 (31.0)	6 (22.2)	2 (25.0)	64 (30.0)
obese	23 (31.1)	1 (5.9)	27 (31.0)	2 (7.4)	3 (37.5)	56 (26.3)
unknown	5 (6.8)	0 (0.0)	13 (14.9)	3 (11.1)	2 (25.0)	23 (10.8)
History of Barrett's Esophagus (N, %)						
yes	50 (67.6)	3 (17.6)	60 (69.0)	4 (14.8)	8 (100)	125 (58.7)
no	24 (32.4)	14 (82.4)	27 (31.0)	23 (85.2)	0 (0.0)	88 (41.3)
History of smoking (N,%)						
yes	56 (75.7)	14 (82.4)	64 (73.6)	22 (81.5)	5 (62.5)	161 (75.6)
no	15 (20.3)	2 (11.8)	14 (16.1)	2 (7.4)	2 (25.0)	35 (16.4)
missing	3 (4.1)	1 (5.9)	9 (10.3)	3 (11.1)	1 (12.5)	17 (8.0)
Clinical Stage (N, %)						
0	2 (2.7)	0 (0.0)	3 (3.4)	0 (0.0)		
I	35 (47.3)	1 (5.9)	12 (13.8)	1 (3.7)		

II	5 (6.8)	6 (35.3)	36 (41.4)	12 (44.4)
III	26 (35.1)	1 (5.9)	28 (32.2)	12 (44.4)
IV	5 (6.8)	9 (52.9)	7 (8.0)	2 (7.4)
missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neoadjuvant therapy (N, %)	44 (59.5)	9 (52.9)	52 (59.8)	18 (66.7)
Survival (days), mean ± SD	1922.9 +/- 1813.0	1924.0 +/- 1872.0	1848.7 +/- 1754.4	1699 .2+/- 1911.4

Table S1. NCIMD case control cohort study sample demographics

Validation Cohort (The Cancer Genome Atlas – RNA-seq Samples)

Description	Esophageal adeno- carcinoma tissues	Esophageal squamous cell carcinoma tissue	Esophageal adeno- carcinoma- adjacent tissues	Esophageal squamous cell carcinoma- adjacent tissue	Total
N samples	28	31	7	0	66
Sex (N, %)					
Male	22 (78.6)	28 (90.3)	5 (71.4)	0 (0.0)	55 (83.3)
Female	6 (21.4)	3 (9.7)	2 (28.6)	0 (0.0)	11 (16.7)
Race (N, %)					
European American	23 (82.1)	10 (32.3)	7 (100.0)	0 (0.0)	40 (60.6)
African American	0 (0.0)	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.5)
Asian American	1 (3.6)	20 (64.5)	0 (0.0)	0 (0.0)	21 (31.8)
Other	4 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	4 (6.1)
Age, mean $\pm$ SD	67.2 +/- 13.2	58.6 +/- 11.1	75.7 +/- 6.9	N/A	64.1 +/- 12.9
BMI (N, %)					
underweight	1 (3.6)	3 (9.7)	0 (0.0)	0 (0.0)	4 (6.1)
normal weight	7 (25.0)	23 (74.2)	1 (14.3)	0 (0.0)	31 (47.0)
overweight	8 (28.6)	2 (6.5)	5 (71.4)	0 (0.0)	11 (16.7)
obese	11 (39.3)	1 (3.2)	1 (14.3)	0 (0.0)	17 (25.8)
unknown	1 (3.6)	2 (6.5)	0 (0.0)	0 (0.0)	3 (4.6)
History of Barrett's Esophagus (N, %)					
yes	7 (25.0)	0 (0.0)	2 (28.6)	0 (0.0)	9 (13.6)
no	17 (60.7)	13 (41.9)	5 (71.4)	0 (0.0)	35 (53.0)

missing	4 (14.3)	18 (58.1)	0 (0.0)	0 (0.0)	22 (33.3)
History of smoking (N,%)					
yes	19 (67.9)	17 (54.8)	4 (57.1)	0 (0.0)	40 (60.6)
no	9 (32.1)	14 (0.452)	3 (42.9)	0 (0.0)	26 (39.4)
Clinical Stage (N, %)					
0	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
I	6 (21.3)	3 (9.7)	3 (42.9)	0 (0.0)	
II	7 (25.0)	18 (58.0)	1 (14.3)	0 (0.0)	
III	7 (25.0)	8 (25.8)	2 (28.6)	0 (0.0)	
IV	1 (3.6)	1 (3.2)	0 (0.0)	0 (0.0)	
missing	7 (25.0)	1 (3.2)	1 (14.3)	0 (0.0)	
Survival (days), mean $\pm$ SD	444.0 +/- 465.0	452.0 +/- 432.0	313.0 +/- 423.0	N/A	

Table S2. TCGA RNA-seq cohort sample demographics

Validation Cohort (The Cancer Genome Atlas – Whole Genome Sequenced Samples)					
Description	Esophageal adeno- carcinoma tissues	Esophageal squamous cell carcinoma tissue	Esophageal adeno- carcinoma- adjacent tissues	Esophageal squamous cell carcinoma- adjacent tissue	Total
N samples	15	29	16	35	95
Sex (N, %)					
Male	11 (73.3)	25 (86.2)	11 (68.8)	30 (85.7)	77 (81.1)
Female	4 (26.7)	4 (13.8)	5 (31.2)	5 (14.3)	18 (18.9)
Race (N, %)					
European American	14 (93.3)	12 (41.4)	16 (100.0)	13 (37.1)	55 (57.9)
African American	0 (0.0)	1 (3.5)	0 (0.0)	2 (5.7)	3 (3.2)
Asian American	1 (6.7)	16 (55.2)	0 (0.0)	20 (57.1)	37 (38.9)
Other	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Age, mean $\pm$ SD	70.8 +/- 11.2	60.2 +/- 11.0	73.3 +/-8.5	59.6 +/- 11.3	63.9 +/- 12.1
BMI (N, %)					
underweight	0 (0.0)	3 (10.3)	0 (0.0)	4 (11.4)	7 (7.4)
normal weight	4 (26.7)	18 (62.1)	4 (25.0)	23 (65.7)	49 (51.6)
overweight	2 (13.3)	5 (17.2)	2 (12.5)	5 (14.3)	14 (14.7)
obese	8 (53.3)	1 (3.5)	9 (56.2)	1 (2.9)	19 (20.0)
unknown	1 (6.7)	2 (6.9)	1 (6.3)	2 (5.7)	6 (6.3)

**History of Barrett's
Esophagus (N, %)**

yes	4 (26.7)	0 (0.0)	5 (31.2)	0 (0.0)	9 (9.5)
no	8 (53.3)	13 (44.8)	8 (50.0)	16 (45.7)	45 (47.4)
missing	3 (20.0)	16 (55.2)	3 (18.8)	19 (54.3)	41 (43.2)

**History of smoking
(N,%)**

yes	9 (60.0)	14 (48.3)	11 (68.8)	15 (42.9)	49 (51.6)
no	6 (40.0)	15 (51.7)	5 (31.2)	20 (57.1)	46 (48.4)

**Clinical Stage (N,
%)**

0	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
I	5 (33.3)	2 (6.9)	7 (43.8)	2 (5.7)	
II	4 (26.7)	15 (51.7)	4 (25.0)	20 (57.1)	
III	3 (20.0)	9 (31.0)	2 (12.5)	9 (25.7)	
IV	1 (6.7)	2 (6.9)	1 (6.3)	2 (5.7)	
missing	2 (13.3)	1 (3.4)	2 (12.5)	2 (5.7)	

Survival (days), mean $\pm$ SD	608.0 +/- 275.0	397.0 +/- 501.0	560.0 +/- 292.0	361.0 +/- 475.0	
--	--------------------	--------------------	--------------------	--------------------	--

Table S3. TCGA RNA-seq cohort sample demographics

Species	Mean % Abundance in Tumor Samples		
	16S rRNA	WGS	RNAseq
<i>Streptococcus</i> spp.*	20.17	15.52	1.11
<i>Prevotella melaninogenica</i>	1.99	10.25	0.34
<i>Fusobacterium nucleatum</i>	4.38	6.31	2.07
<i>Veillonella parvula</i>	1.34	4.61	0.42
<i>Helicobacter pylori</i>	0.18	3.23	0.01
<i>Haemophilus influenzae</i>	0.22	2.86	0.66
<i>Prevotella denticola</i>	0.13	2.22	0.17
<i>Prevotella intermedia</i>	0.80	1.81	0.05
<i>Campylobacter concisus</i>	0.14	1.60	0.03
<i>Staphylococcus aureus</i>	0.54	1.23	0.16
<i>Rothia mucilaginosa</i>	3.16	1.09	0.54
<i>Haemophilus parainfluenzae</i>	1.74	1.09	0.09
<i>Selenomonas sputigena</i>	1.96	1.01	0.08
<i>Bacteroides fragilis</i>	0.16	0.77	0.03
<i>Stenotrophomonas maltophilia</i>	3.88	0.47	0.41
<i>Gemella haemolysans</i>	1.55	0.32	0.16

**S. oralis*, *S. mitis*, *S. pneumoniae*, *S. parasanguinis*, *S. salivarius*

Species	Cohort Exclusion	Comparative Statistical Results					Statistical Frequency Results		
		GLM P-value	GLMM P-value	Mann-Whitney Tumor vs Non-Tumor			Fisher's Exact Test for Tumor vs Normal		
		Tumor vs Non-tumor	Tumor vs Non-tumor	16SrRNA	WGS	RNAseq	16SrRNA	WGS	RNAseq
<i>Fusobacterium nucleatum</i>	No WGS Blood	0.0870	0.0054	0.0000	0.4602	0.0524	0.0004	0.8134	0.0471
<i>Fusobacterium nucleatum</i>	WGS Non-tumor w/ Blood	0.0015	0.0001	0.0000	0.0074	0.0524	0.0004	0.0253	0.0471

Species	Cohort Exclusion	Comparative Statistical Results					Statistical Frequency Results		
		GLM P-value	GLMM P-value	Mann-Whitney Tumor vs Non-Tumor			Fisher's Exact Test for Tumor vs Normal		
		Tumor vs Non-tumor	Tumor vs Non-tumor	16SrRNA	WGS	RNAseq	16SrRNA	WGS	RNAseq
<i>Streptococcus</i> spp	No WGS Blood	0.3952	0.5795	0.0154	0.6974	0.2194	0.0228	0.7872	0.1066
<i>Streptococcus</i> spp	WGS Non-tumor w/ Blood	0.0873	0.0151	0.0154	0.0346	0.2194	0.0228	0.0127	0.1066

Species	Cohort Exclusion	Comparative Statistical Results					Statistical Frequency Results		
		GLM P-value	GLMM P-value	Mann-Whitney Tumor vs Non-Tumor			Fisher's Exact Test for Tumor vs Normal		
		Tumor vs Non-tumor	Tumor vs Non-tumor	16SrRNA	WGS	RNAseq	16SrRNA	WGS	RNAseq
<i>Campylobacter concisus</i>	No WGS Blood	0.2805	0.4084	0.0047	0.6204	0.0388	0.0045	1.0000	0.0419
<i>Campylobacter concisus</i>	WGS Non-tumor w/ Blood	0.2148	0.1485	0.0047	0.0077	0.0388	0.0045	0.0089	0.0419

Species	Cohort Exclusion	Comparative Statistical Results					Statistical Frequency Results		
		GLM P-value	GLMM P-value	Mann-Whitney Tumor vs Non-Tumor			Fisher's Exact Test for Tumor vs Normal		
		Tumor vs Non-tumor	Tumor vs Non-tumor	16SrRNA	WGS	RNAseq	16SrRNA	WGS	RNAseq
<i>Prevotella melaninogenica</i>	No WGS Blood	0.9021	0.8310	0.9459	0.1724	0.0797	1.0000	0.1254	0.1884
<i>Prevotella melaninogenica</i>	WGS Non-tumor w/ Blood	0.0002	0.0006	0.9459	0.0000	0.0797	1.0000	0.0000	0.1884

Table S4. Mean relative abundance across cohorts sorted first by species in WGS and comparative statistical comparisons of four taxa enriched in tumors vs non-tumor adjacent.

	<i>Campylobacter</i>			<i>Fusobacterium</i>			<i>Prevotella</i>			<i>Streptococcus</i>		
Genus	NCIMD	RNA	WGS	NCIMD	RNA	WGS	NCIMD	RNA	WGS	NCIMD	RNA	WGS
<i>Campylobacter</i>	NA	NA	NA	0.0977	0.3314	0.3733	0.0692	0.3494	0.4239	-0.0923	0.1915	0.3829
<i>Fusobacterium</i>	0.0977	0.3314	0.3733	NA	NA	NA	0.3371	0.609	0.6038	-0.2083	0.2132	0.0937
<i>Leptotrichia</i>	0.0072	0.3211	0.3086	0.2125	0.5202	0.4781	0.1792	0.5202	0.4643	-0.0326	0.2232	0.2
<i>Neisseria</i>	-0.0485	-0.0019		0.0138	-0.0152		0.0233	0.1697		0.1532	0.4782	
<i>Prevotella</i>	0.0692	0.3494	0.4239	0.3371	0.609	0.6038	NA	NA	NA	0.0637	0.2522	0.3786
<i>Selenomonas</i>	0.0531		0.3642	0.1159		0.5826	0.1559		0.5889	-0.0460		0.0997
<i>Streptococcus</i>	-0.0923	0.1915	0.3829	-0.2083	0.2132	0.0937	0.0637	0.2522	0.3786	NA	NA	NA
<i>Veillonella</i>	-0.0134	0.3612	0.4588	0.0137	0.1892	-0.123	0.2569	0.4912	0.4286	0.2815	0.4452	0.4925

Table S5. Concordance between taxonomic co-occurrence and co-exclusion